{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/437096556"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "This study is a 90 subject, placebo-controlled, double-blind, parallel-design, multiple-dose, six-week study assessing NBI-98854 in doses up to 75mg once-a-day against placebo in tardive dyskinesia patients with underlying mood disorders, schizophrenia and schizoaffective disorders, and gastrointestinal disorders." ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "prnewswire.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/224364433"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/437096556"] } } }
